Literature DB >> 16206677

[A clinical trial of oxymatrine in treating chronic viral hepatitis type B].

Y Yu1, C Si, Z Zeng, Q Wang, X Zhou, Q Zhang, Z Huang, L Zhang, G Qiao.   

Abstract

OBJECTIVE: To investigate the therapeutic effect of oxymatrine on chronic viral hepatitis type B.
METHODS: 303 patients were randomly allocated either to a treatment group or a control group. The treatment group consisted of 253 patients treated with intravenous or intra-muscular injection of oxymatrine and oral oxymatrine capsule. Oral tiopronin was used in the control group.
RESULTS: At the end of treatment, the rate of normal ALT was similar among the different groups. The rate of normal ALT was 53.3% - 58.3% in the three oxymatrine groups six months after the end of treatment. It was higher than that of the tiopronin group (P < 0.05). After a follow up of six months, the rate of negative HBeAg was 30.0% - 40.9% in the three oxymatrine groups. It was higher than that of the tiopronin group (16.7%). The rate of negative HBV DNA was 39.2% - 49.5% in the three oxymatrine groups. It was also higher than that of the tiopronin group.
CONCLUSION: Oxymatrine can improve the liver function and increase the negative rate of HBeAg and HBV DNA in the patients with chronic hepatitis B. The therapeutic effect of oxymatrine will persist after the cessation of administration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 16206677

Source DB:  PubMed          Journal:  Zhonghua Nei Ke Za Zhi        ISSN: 0578-1426


  1 in total

1.  T cell--associated immunoregulation and antiviral effect of oxymatrine in hydrodynamic injection HBV mouse model.

Authors:  Xiuxiu Sang; Ruilin Wang; Yanzhong Han; Cong'en Zhang; Honghui Shen; Zhirui Yang; Yin Xiong; Huimin Liu; Shijing Liu; Ruisheng Li; Ruichuang Yang; Jiabo Wang; Xuejun Wang; Zhaofang Bai; Xiaohe Xiao
Journal:  Acta Pharm Sin B       Date:  2017-05-02       Impact factor: 11.413

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.